We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

Fund managers haven’t disclosed any holdings of RNAM yet.

RNAM Hedge Fund Activity: Q1 2026 in Review

1 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2026, worth a combined $236K — down 100% from $10.8B a quarter earlier.

Sellers outnumbered buyers: 335 funds closed out of RNAM and 0 opened new positions — a net loss of 335 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $927M sold.

  • 1 institutional investor held Avidity Biosciences (RNAM) as of Q1 2026, down from 343 in Q4 2025.
  • Funds reported $236K of Avidity Biosciences stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Avidity Biosciences positions in Q1 2026 and 335 closed out, a net change of -335 holders.
  • The largest Avidity Biosciences seller in Q1 2026 was BlackRock, an estimated $927M sold.

Based on aggregated 13F filings for Q1 2026.